Savara Inc. (SVRA)

AI Score

Unlock

2.72

0.12 (4.62%)

At close: Apr 09, 2025, 3:59 PM

2.65

-2.46%

Pre-market: Apr 10, 2025, 09:03 AM EDT

Dividends

No dividend history available for Savara Inc..

Pro Subscription

Upgrade now for unlimited access to all data and tools.

Dividend Definition

Dividends are payments made by a company to its shareholders, typically derived from its profits. They represent a portion of earnings distributed to investors as a reward for holding shares. Dividends do not account for retained earnings or reinvestments and are therefore different from a company's total profits.

Related Stocks

Company	Dividend Yield

Dividend Rankings

SVRA News

2 days ago · Savara Announces Encore Presentations From the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at Two Upcoming Scientific Conferences - businesswire.com
1 week ago · Savara Reports Fourth Quarter and Year End 2024 Financial Results and Provides Business Update - businesswire.com
2 weeks ago · Savara Enters Into Non-Dilutive Debt Financing for up to $200M With Hercules Capital - businesswire.com
2 weeks ago · Savara Completes Submission of the Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* as a Treatment for Autoimmune Pulmonary Alveolar Proteinosis (aPAP) - businesswire.com
3 weeks ago · Savara to Present New Data From the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society International Conference 2025 - businesswire.com
1 month ago · Savara Announces Participation in the Leerink Global Healthcare Conference - businesswire.com
1 month ago · Savara Announces New Employment Inducement Grant - businesswire.com
2 months ago · Savara Announces Manuscript on Long-Term Outcomes With Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Published in ERJ Open Research - businesswire.com